eXoZymes is a biomanufacturing company that uses AI-designed enzymes called "exozymes" to produce valuable chemicals sustainably in cell-free bioreactors, offering advantages over traditional chemical synthesis, extraction, and cell-based production methods. The company initially targets low-volume, high-value natural products and derivatives for nutraceuticals and active pharmaceutical ingredients, with a lead asset showing significant metabolic benefits and pilot-scale production capability. eXoZymes generates revenue through multiple commercialization routes—including spin-outs, joint ventures, and licensing—while charging upfront R&D fees, milestone payments, and future royalties; the business is supported by government grants and a proprietary enzyme platform licensed from academic institutions.